CryoLife, Inc. Announces Conference Call at 8:30 AM Tomorrow To Discuss FDA Letter
The conference call will be hosted by Steven G. Anderson, President and CEO, D. Ashley Lee, Vice President and CFO, and James C. Vander Wyk, Ph.D., Vice President of Regulatory Affairs and Quality Assurance. Shareholders interested in participating in the call may do so by calling (973) 582-2713 a few minutes prior to 8:30 am Eastern time. Those interested in listening to a replay of the teleconference may do so by calling (toll free) 877-519-4471 or (973) 341-3080. The identification number for the replay is 3358637. The replay will be available through Friday June 28, 2002.
Founded in 1984, CryoLife, Inc. is the leader in the development and commercialization of implantable living human tissues for use in cardiovascular, vascular and orthopaedic surgeries throughout the United States and Canada. The Company's BioGlue(R) surgical adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels and is CE marked in the European Community and approved in Canada and Australia for use in vascular and pulmonary sealing and repair. The Company also manufactures the SynerGraft(R) heart valve and the SynerGraft vascular graft, the world's first tissue-engineered heart valve and vascular replacements, and the CryoLife-O'Brien(R) and CryoLife-Ross(R) stentless porcine heart valves, which are CE marked for distribution, within the European Community. The human heart valves and vascular grafts processed by CryoLife using the SynerGraft technology are distributed in the U.S., under the trade names of CryoValve(R)SG and CryoVein(R)SG, respectively.
For additional information about the company, visit CryoLife's web site: http://www.cryolife.com
Contact: D. Ashley Lee
Vice President, Chief Financial Officer
(800) 438-8285